Free Trial
NASDAQ:MOLN

Molecular Partners H1 2025 Earnings Report

Molecular Partners logo
$3.54 -0.02 (-0.67%)
Closing price 08/14/2025 03:50 PM Eastern
Extended Trading
$3.54 0.00 (-0.03%)
As of 08/14/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Molecular Partners EPS Results

Actual EPS
N/A
Consensus EPS
-$0.53
Beat/Miss
N/A
One Year Ago EPS
N/A

Molecular Partners Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Molecular Partners Announcement Details

Quarter
H1 2025
Time
Before Market Opens
Conference Call Date
Tuesday, August 26, 2025
Conference Call Time
8:00AM ET

Conference Call Resources

Molecular Partners Earnings Headlines

This stock could leave NVDA in the dust
Investing Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla and Nvidia are all on the verge of major disruption. To help protect anyone with money invested in them, he's sharing three exciting stocks to replace them with. He gives away the names and tickers completely free in his brand-new "Sell This, Buy That" broadcast.
Molecular Partners AG (MOLN) - Yahoo Finance
See More Molecular Partners Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Molecular Partners? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Molecular Partners and other key companies, straight to your email.

About Molecular Partners

Molecular Partners (NASDAQ:MOLN) AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

View Molecular Partners Profile

More Earnings Resources from MarketBeat